#1 Clinical Trials Search in Europe

Colistimethate Sodium

Colistimethate sodium, also known as colistin, is an antibiotic being studied in clinical trials for its effectiveness against multidrug-resistant gram-negative bacterial infections. Researchers are investigating its use through various administration routes, including intravenous and inhaled forms, to treat conditions like ventilator-associated pneumonia and infections in patients with compromised immune systems. These trials aim to determine optimal dosing, safety profiles, and efficacy in different patient populations.

Table of Contents

What is Colistimethate Sodium?

Colistimethate sodium, also known as colistin, is an antibiotic medication used to treat various bacterial infections. It belongs to a class of antibiotics called polymyxins[1]. This drug has been in use since the 1950s but has recently gained renewed interest due to its effectiveness against certain hard-to-treat bacteria[3].

Colistimethate sodium is known by several other names, including:

  • Colistin
  • Polymyxin E
  • CMS
  • Colimycin
  • Coly-Mycin

These alternative names may be used interchangeably in medical settings or on medication labels[4][7].

What Conditions Does Colistimethate Sodium Treat?

Colistimethate sodium is primarily used to treat infections caused by certain types of bacteria that are resistant to many other antibiotics. Some of the conditions it may be used to treat include:

  • Hospital-acquired pneumonia: This is a lung infection that develops during a hospital stay, often in patients on ventilators[2].
  • Ventilator-associated pneumonia: A type of lung infection that occurs in people who are on mechanical ventilation[8].
  • Infections caused by multidrug-resistant (MDR) gram-negative bacteria: These are bacteria that have become resistant to many common antibiotics[3].
  • Infections in people with cystic fibrosis: Colistimethate sodium may be used to treat certain bacterial infections in people with this genetic disorder[3].
  • Central nervous system infections: In some cases, colistimethate sodium may be used to treat infections in the brain or spinal cord[9].

How Does Colistimethate Sodium Work?

Colistimethate sodium works by attacking the cell membranes of certain bacteria. When administered, it breaks down into its active form, colistin, which then binds to and disrupts the outer membrane of susceptible bacteria. This action causes the bacteria’s cell contents to leak out, ultimately killing the bacteria[1].

It’s important to note that colistimethate sodium is particularly effective against a group of bacteria known as “gram-negative” bacteria. These include bacteria like Pseudomonas aeruginosa, Acinetobacter baumannii, and certain types of Klebsiella, which can cause serious infections and are often resistant to other antibiotics[3].

How is Colistimethate Sodium Administered?

Colistimethate sodium can be administered in several ways, depending on the type and location of the infection being treated:

  • Intravenous (IV) injection: The medication is given directly into a vein. This is the most common method for treating systemic infections[1].
  • Inhaled (nebulized): The medication is turned into a fine mist that can be inhaled into the lungs. This method is often used for lung infections, particularly in patients with cystic fibrosis[1].
  • Intrathecal or intraventricular: In some cases of central nervous system infections, the medication may be administered directly into the fluid surrounding the brain and spinal cord[9].

The dosage and duration of treatment can vary depending on the type and severity of the infection, the patient’s kidney function, and other factors. It’s crucial to follow the prescribed dosage and complete the full course of treatment as directed by your healthcare provider[7].

Effectiveness of Colistimethate Sodium

Colistimethate sodium has shown effectiveness in treating various bacterial infections, particularly those caused by multidrug-resistant organisms. Its efficacy is often measured by:

  • Clinical response: This refers to the improvement or resolution of infection symptoms[10].
  • Microbiological cure: This means that the bacteria causing the infection are no longer detectable in laboratory tests[10].

Research is ongoing to determine the most effective dosing regimens and to compare colistimethate sodium with other antibiotics or combination therapies[10].

Potential Side Effects

Like all medications, colistimethate sodium can cause side effects. Some of the potential side effects include:

  • Nephrotoxicity: This means damage to the kidneys. It’s one of the most significant concerns with colistimethate sodium use[6].
  • Neurotoxicity: This can include symptoms like dizziness, weakness, facial and peripheral paresthesia (tingling sensations), visual disturbances, confusion, ataxia (loss of muscle control), and neuromuscular blockade[3].
  • Respiratory effects: When inhaled, colistimethate sodium can sometimes cause coughing or bronchospasm (tightening of the airways)[1].

Your healthcare provider will monitor you closely for these side effects during treatment. It’s important to report any unusual symptoms or side effects to your doctor promptly.

Current Research and Future Directions

Researchers are continually studying colistimethate sodium to better understand its effects and optimize its use. Some areas of current research include:

  • Comparing colistimethate sodium to other antibiotics or combination therapies for various infections[10].
  • Investigating the use of inhaled colistimethate sodium to prevent ventilator-associated pneumonia in children[8].
  • Studying the pharmacokinetics (how the drug moves through the body) and pharmacodynamics (how the drug affects the body) of colistimethate sodium in different patient populations[3].
  • Exploring the use of colistimethate sodium in treating central nervous system infections[9].

These ongoing studies aim to improve our understanding of colistimethate sodium and enhance its effectiveness while minimizing potential side effects.

Aspect Details
Main Uses Treatment of multidrug-resistant gram-negative bacterial infections, including ventilator-associated pneumonia and hospital-acquired pneumonia
Administration Routes Intravenous infusion, inhaled nebulization, sometimes in combination
Patient Populations Critically ill patients, cystic fibrosis patients, cancer patients, individuals on mechanical ventilation
Key Side Effects Monitored Nephrotoxicity, neurotoxicity, respiratory issues (e.g., bronchospasm)
Research Objectives Optimal dosing, safety profiles, efficacy, pharmacokinetics, potential for infection prevention
Challenges Balancing efficacy with side effects, preventing antibiotic resistance

FAQ

  • What is colistimethate sodium used for in clinical trials? Colistimethate sodium is being studied for treating multidrug-resistant gram-negative bacterial infections, including ventilator-associated pneumonia, hospital-acquired pneumonia, and infections in patients with conditions like cystic fibrosis or cancer.
  • How is colistimethate sodium administered in these trials? The drug is being tested in various forms, including intravenous infusions and inhaled nebulized solutions. Some trials are exploring combination therapies with both intravenous and inhaled administration.
  • What are the main side effects being monitored in colistimethate sodium trials? The primary side effects being closely monitored include nephrotoxicity (kidney damage), neurotoxicity (nerve damage), and respiratory issues like bronchospasm. Researchers are also watching for any development of antibiotic resistance.
  • Who are the typical participants in these clinical trials? Participants vary depending on the study, but often include critically ill patients, those with cystic fibrosis, cancer patients, and individuals on mechanical ventilation. Some trials also involve healthy volunteers for pharmacokinetic studies.
  • What are researchers hoping to learn from these clinical trials? Researchers aim to determine the optimal dosing regimens, assess the drug's safety and efficacy, understand its pharmacokinetics in different patient populations, and evaluate its potential for preventing infections like ventilator-associated pneumonia.

Ongoing Clinical Trials on Colistimethate Sodium

  • Study on Inhaled Colistimethate Sodium for Adults with Bronchiectasis and New Asymptomatic Pseudomonas Aeruginosa Infection

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study Comparing Ciprofloxacin, Colistimethate Sodium, and Ceftazidime for Treating Early Airway Infection in Adults with Bronchiectasis

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness and Safety of 7 vs. 14 Days of Antibiotic Treatment with Meropenem for Patients with Pseudomonas Aeruginosa Blood Infection

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study of Aztreonam-Avibactam and Metronidazole for Children with Serious Gram-Negative Bacterial Infections

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Greece Hungary Spain

  • Study on Inhaled Tobramycin and Colistimethate Sodium for Adults with Chronic Bronchial Infection in Bronchiectasis

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Avibactam and Drug Combination for Treating Severe Infections in Patients

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece

Glossary

  • Colistimethate sodium: An antibiotic used to treat infections caused by certain bacteria. It's a prodrug that is converted to its active form, colistin, in the body.
  • Multidrug-resistant (MDR): Bacteria that have become resistant to multiple types of antibiotics, making infections difficult to treat.
  • Gram-negative bacteria: A class of bacteria that do not retain crystal violet dye in the Gram staining protocol. They are often resistant to many antibiotics.
  • Ventilator-associated pneumonia (VAP): A type of lung infection that occurs in people who are on mechanical ventilation breathing machines in hospitals.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Nephrotoxicity: The poisonous effect of some substances, including certain medications, on the kidneys.
  • Neurotoxicity: The poisonous effect of some substances on the nervous system.
  • Bronchospasm: A sudden constriction of the muscles in the walls of the bronchioles, causing difficulty in breathing.
  • Minimum Inhibitory Concentration (MIC): The lowest concentration of an antibiotic that prevents visible growth of a bacterium.
  • Carbapenem-resistant: Bacteria that are resistant to a class of antibiotics called carbapenems, which are often used as a last resort for treating serious infections.

References

  1. https://clinicaltrials.gov/study/NCT01863719
  2. https://clinicaltrials.gov/study/NCT01940731
  3. https://clinicaltrials.gov/study/NCT02288429
  4. https://clinicaltrials.gov/study/NCT03397914
  5. https://clinicaltrials.gov/study/NCT02966457
  6. https://clinicaltrials.gov/study/NCT02482961
  7. https://clinicaltrials.gov/study/NCT01449838
  8. https://clinicaltrials.gov/study/NCT06488794
  9. https://clinicaltrials.gov/study/NCT06702943
  10. https://clinicaltrials.gov/study/NCT06570850